The 2026 Ebola outbreak in the Democratic Republic of the Congo (DRC) has surpassed 10,000 confirmed cases, highlighting the importance of timely case identification, reliable laboratory testing, and effective infection prevention.

According to the U.S. Centers for Disease Control and Prevention (CDC), as of October 28, 2026, the DRC had reported 10,274 confirmed cases and 4,992 confirmed deaths. The outbreak has affected eight provinces, while related cases have also been reported in other countries.

The outbreak is caused by Bundibugyo virus, an Ebola virus species that requires particular attention when selecting diagnostic methods. These developments reinforce the need for healthcare institutions, laboratories, and diagnostic suppliers to understand what different Ebola tests can—and cannot—establish.

Source: CDC — Ebola Outbreak: Current Situation

Why Does Accurate Ebola Testing Matter?

Ebola virus disease can initially present with symptoms such as fever, fatigue, headache, and muscle pain. These symptoms overlap with those of other infectious diseases, making clinical assessment alone insufficient to confirm an infection.

Laboratory testing plays an essential role in identifying suspected cases and supporting public health responses. However, selecting a suitable test requires more than considering speed or convenience.

Healthcare institutions should evaluate several factors:

• Target virus: Does the test detect the specific Ebola virus species associated with the suspected infection?
• Detection method: Is the test based on antigen detection or molecular methods such as RT-PCR?
• Performance evidence: Are sensitivity, specificity, and other performance claims supported by appropriate data?
• Specimen requirements: Is the intended specimen type compatible with the test’s validated instructions?
• Regulatory status: Is the product authorized, cleared, or otherwise appropriately evaluated for its intended use and destination market?

These considerations are particularly important during an outbreak involving a virus species for which diagnostic options may differ from those available for other Ebola virus species.

Ebola Antigen Tests and Molecular Diagnostics: Understanding the Difference

Ebola diagnostic tests are not interchangeable. Antigen rapid diagnostic tests detect specific viral proteins, while molecular tests such as RT-PCR detect viral genetic material.

Both approaches have distinct technical requirements, performance characteristics, and limitations. A rapid result does not automatically mean that a test is suitable for every stage of infection or every Ebola virus species.

The current Bundibugyo virus outbreak makes this distinction especially important. In its May 22, 2026 recommendations, the Africa Centres for Disease Control and Prevention (Africa CDC) reported that the antigen rapid diagnostic tests assessed at that time did not meet the required target product profile for use in the current outbreak response.

This finding highlights why diagnostic products must be evaluated against the specific pathogen, intended use, and available evidence rather than selected solely on the basis of their product names or advertised speed.

Source: Africa CDC — Molecular Diagnostic Tests (RT-PCR) for Ebola Virus Bundibugyo Strain

What Should Laboratories Consider When Choosing an Ebola Test Kit?

For laboratories, healthcare organizations, distributors, and medical procurement teams, evaluating an Ebola test kit should begin with documented suitability rather than brand recognition alone.

A structured evaluation should include the manufacturer’s technical documentation, intended-use statement, validated specimen types, analytical and clinical performance evidence, quality-management information, and applicable regulatory documentation.

Supply reliability, storage conditions, shelf life, packaging, and technical support may also be important when preparing for public health emergencies.

For procurement teams comparing an Ebola virus test kit manufacturer, these details provide a more meaningful basis for decision-making than unsupported claims that a product is the best or most accurate option available.

HCY: A Diagnostic Product Manufacturer to Evaluate

Shenzhen Huachenyang Technology Co., Ltd. (HCY) is a medical diagnostic and consumables manufacturer established in 2008, with business activities spanning research and development, manufacturing, and sales.

HCY lists an Ebola Virus Antigen Rapid Test Kit among its diagnostic products. For laboratories and professional buyers evaluating this product, the appropriate next step is to review its documented detection target, intended use, specimen requirements, performance evidence, and applicable regulatory status.

In particular, buyers should confirm whether the product has evidence supporting detection of Bundibugyo virus before considering it for applications related to the current outbreak. A product’s designation as an Ebola antigen test does not, by itself, establish suitability for every Ebola virus species or clinical setting.

For additional product information and supplier enquiries, visit HCY’s official website.

Looking Ahead: Better-Informed Diagnostic Decisions

The 2026 Ebola outbreak demonstrates that effective diagnostic preparedness depends on more than access to testing products. It requires appropriate test selection, reliable laboratory processes, evidence-based evaluation, and coordination between healthcare institutions and diagnostic suppliers.

As the outbreak continues to evolve, laboratories and procurement teams should follow updates from the WHO, CDC, and Africa CDC while reviewing the suitability and documentation of diagnostic products for their intended applications.

For HCY and other diagnostic manufacturers, transparent product information and verifiable performance evidence are essential to helping professional buyers make informed decisions.

Keep Hands Clean

From sharing treats to touching door handles and decorations, hands come into contact with many surfaces throughout Halloween activities. Washing hands with soap and water at key moments, especially before eating and after using the restroom, helps reduce the spread of germs.

Clean Shared Surfaces

Party tables, frequently touched objects, and shared activity areas deserve regular attention. Cleaning visibly dirty surfaces and following appropriate disinfection instructions can support a healthier environment at home, in schools, and at community events.

Make Hygiene Part of the Celebration

Good hygiene does not have to interrupt the fun. Keeping handwashing supplies available, handling food safely, and maintaining clean shared spaces are practical steps that everyone can follow.

At Huachenyang (HCY), we believe that protecting health starts with attention to everyday details. As a medical device manufacturer specializing in sampling products and related healthcare solutions, HCY supports healthcare professionals and partners with products designed for reliable sample collection and hygiene-related applications.

This Halloween, enjoy the treats, embrace the traditions, and remember: small habits can make a meaningful difference in keeping our communities healthier.

Happy Halloween 2026 from HCY!

Early Flu Activity Is Rising in the United States

According to the U.S. Centers for Disease Control and Prevention (CDC), influenza activity remained low nationally in the week ending October 10, 2026, but several indicators had been increasing since late August and early September.

The percentage of clinical laboratory specimens testing positive for influenza rose from 3.9% in the previous week to 5.0%. Although these figures do not indicate how severe the full season will be, they demonstrate why respiratory virus surveillance and diagnostic readiness matter early in the season.

The World Health Organization (WHO) estimates that seasonal influenza causes approximately one billion infections worldwide each year, including 3–5 million cases of severe illness. These long-term estimates underline the continuing global burden of influenza, even though the timing and severity of each season vary.

Why the 2026–2027 Season Deserves Attention

Influenza viruses continue to evolve, which is why seasonal vaccine compositions are reviewed and updated regularly. For the 2026–2027 Northern Hemisphere season, WHO recommended updated vaccine virus components based on global surveillance data. In the United States, all three components of the seasonal influenza vaccine were updated compared with the previous season.

These updates reflect the changing nature of influenza viruses, but they do not mean that a more severe season is inevitable. Ongoing surveillance and appropriate diagnostic testing remain important for understanding which viruses are circulating and supporting clinical decisions.

Reliable Testing Starts Before the Laboratory

Accurate respiratory testing depends on more than laboratory instruments and diagnostic assays. Specimen collection, handling, and transport are also important parts of the testing process.

The appropriate swab must match the intended specimen type and diagnostic method. Flocked swabs are used in many respiratory specimen collection workflows, while viral transport medium (VTM) may be required when specimens need to be transported to another testing facility.

Storage conditions, transport time, and specimen requirements should always follow the applicable test manufacturer’s instructions and laboratory procedures. Poor handling can compromise specimen quality and may lead to repeat collection or testing delays.

Supporting Respiratory Specimen Collection and Transport

As a medical device manufacturer specializing in specimen collection and transport products, Huachenyang (HCY)provides solutions for healthcare and laboratory applications, including flocked swabs and viral transport medium (VTM).

For diagnostic laboratories, healthcare providers, and medical device distributors, selecting compatible collection materials and maintaining standardized handling procedures can help support a consistent respiratory testing workflow throughout flu season.

As influenza activity evolves during the 2026–2027 season, preparation begins with reliable surveillance, appropriate testing, and careful attention to every step from specimen collection to laboratory analysis.

Sources:

• U.S. CDC, Weekly U.S. Influenza Surveillance Report, Week 40, 2026
• WHO, Recommendations for Influenza Vaccine Composition for the 2026–2027 Northern Hemisphere Season
• U.S. CDC, 2026–2027 Flu Season

Dengue may receive less attention when outbreak headlines fade, but the risk has not disappeared. According to the World Health Organization (WHO), approximately 2.2 million dengue cases and more than 1,100 deaths were reported across 97 countries and territories between January and August 2026. Although global reported cases were lower than in the previous two years, several countries continued to experience significant outbreaks.

Bangladesh is a recent reminder of this ongoing threat. In October 2026, Reuters reported a worsening outbreak, with more than 90,000 hospitalizations and hundreds of deaths reported since the beginning of the year. The situation highlights why dengue awareness must remain a public health priority, even when global trends appear to improve.

Recognizing the Risk Beyond the Headlines

Dengue is transmitted primarily by infected Aedes mosquitoes. Fever, headache, muscle pain, and joint pain are common symptoms, but early dengue can resemble other febrile illnesses. Some patients may develop severe dengue, making timely medical assessment essential.

Importantly, warning signs can appear after a fever begins to subside. Severe abdominal pain, persistent vomiting, bleeding, or unusual weakness require urgent medical attention. A falling temperature alone does not guarantee recovery.

Prevention Begins with Awareness and Action

Reducing mosquito breeding sites is a practical first step. Empty standing water from containers, maintain clean surroundings, use appropriate mosquito repellents, and follow local public health guidance. Anyone with a suspected infection should seek medical advice rather than relying on symptoms alone.

Accurate diagnosis also matters. Depending on the stage of illness, healthcare professionals may use molecular tests, NS1 antigen tests, or antibody tests. Reliable diagnostic workflows depend on selecting appropriate tests, following specimen collection and handling requirements, and interpreting results in the clinical context.

Supporting Better Diagnostic Preparedness

At Huachenyang (HCY), we recognize the importance of reliable specimen collection and well-managed diagnostic workflows in healthcare. Through our work in medical specimen collection products and diagnostic consumables, we support the broader laboratory and healthcare ecosystem.

Dengue prevention requires more than a response to an outbreak. It depends on public awareness, responsible community action, timely medical assessment, and reliable diagnostic processes working together.

Dengue may fade from the headlines, but vigilance should never fade from our daily lives.

When Does a Short Swab Design Matter?

In workflows involving limited operating space, small sample containers, or close-range manual handling, a shorter swab may offer practical advantages. Its compact shaft can make the tool easier to position and handle in certain setups, depending on the sampling procedure and operator requirements.

However, swab selection should not rely on length alone. The sampling head dimensions, shaft material, specimen type, and compatibility with downstream testing methods must also be considered.

Choosing the Right Swab for IVD Applications

For in vitro diagnostic (IVD) applications, laboratories should evaluate swab specifications against their intended sampling procedures. Key considerations include specimen compatibility, sample release performance, transport conditions, and the requirements of the relevant assay.

A shorter design is not universally better; its value depends on whether its dimensions suit the intended workflow.

HCY CY-96001 Short Flocked Swab

HCY’s CY-96001 Short Flocked Swab is designed for IVD-related sampling applications. Its compact format and available size options provide choices for different sampling requirements. The product is labeled non-sterile, so users should verify that its status and specifications meet the requirements of their intended application.

By considering swab dimensions alongside specimen requirements and testing workflows, laboratories and diagnostic manufacturers can make more informed decisions when selecting sampling consumables.

For detailed specifications and application guidance, contact HCY.

For Huachenyang, National Day is also a meaningful moment to reflect on our journey and the people who have been part of it.

Founded in Shenzhen in 2008, Huachenyang has grown into a medical device manufacturer focused on in vitro diagnostics (IVD), integrating research and development, manufacturing and sales. Over the years, we have continued to develop our capabilities while building long-term relationships with customers and partners around the world.

From Shenzhen to global markets, every step of our journey has been shaped by cooperation, trust and a shared commitment to healthcare.

Today, Huachenyang continues to move forward with the same mission: developing reliable medical products, supporting our partners and contributing to better healthcare.

National Day is a celebration of where we have come from, but also a reminder to keep looking ahead.

As China celebrates National Day 2026, Huachenyang sincerely thanks our customers, partners and friends around the world for being part of our journey.

May this National Day bring happiness, meaningful moments with family and renewed inspiration for the future.

From China to the world, Huachenyang will continue moving forward together with our partners toward a healthier future.

Happy National Day 2026!

Huachenyang — Health Care for You, Is Our Forever Mission.

As the full moon rises this Mid-Autumn Festival, Shenzhen Huachenyang Technology Co., Ltd. (HCY) would like to extend our warmest wishes to our customers, partners, and friends around the world.

In Chinese culture, the Mid-Autumn Festival is a time for reunion. Families gather under the full moon, share mooncakes, and take a moment to appreciate the people who matter most. The round moon has long been a symbol of togetherness, connection, and good wishes.

For HCY, these ideas have a special meaning.

Since 2008, we have been working in the field of in vitro diagnostics and medical consumables, supporting healthcare and laboratory applications with reliable sample collection and diagnostic products. Behind every product is a simple purpose: helping healthcare professionals collect, preserve, and handle samples more effectively.

As our customers and partners work across different countries and time zones, the Mid-Autumn Festival also reminds us that meaningful connections can cross borders.

This year, as we look toward the moon from different places around the world, HCY is grateful for the trust and cooperation we have built with our global partners.

May this Mid-Autumn Festival bring you and your loved ones health, happiness, and reunion.

Happy Mid-Autumn Festival from HCY!

Health Care for You Is Our Forever Mission.

For healthcare professionals, understanding why drying matters can help improve the consistency and safety of skin preparation.

What Happens After CHG Is Applied?

Many CHG skin-preparation products combine chlorhexidine with alcohol.

After the solution is applied, the alcohol begins to evaporate from the skin. At the same time, chlorhexidine remains on the treated surface and provides its intended antiseptic activity.

If the solution is removed before it has dried, the skin may not receive the intended exposure to the formulation.

This is why healthcare professionals are generally instructed to allow the preparation to air dry rather than wiping it away.

Why Is Drying Especially Important in the Operating Room?

Alcohol-based antiseptics require additional attention because wet alcohol can be flammable.

During surgery, equipment such as electrosurgical devices, lasers, or other potential ignition sources may be present. If alcohol-based antiseptic solution remains wet on the patient’s skin or has pooled around the patient, it can increase fire risk.

Allowing the preparation to dry completely helps reduce this risk.

The important point is that drying is not simply about waiting for the skin to “feel dry.” Healthcare professionals should follow the specific product instructions and ensure that excess solution has not collected beneath the patient or in skin folds.

Is There a Universal CHG Drying Time?

No.

A common mistake is to assume that every CHG applicator should have the same drying time. In reality, drying can be affected by several factors, including:

• CHG and alcohol formulation
• Amount of solution applied
• Size of the preparation area
• Skin folds or anatomical contours
• Temperature and airflow
• Amount of solution that has pooled

Therefore, a fixed drying time should not be applied to every CHG product.

For example, a larger preparation area using a higher volume of solution may naturally require more time to dry than a smaller preparation area.

The manufacturer’s instructions for use (IFU) should always take priority.

Why Should Healthcare Professionals Avoid Blowing or Wiping?

It may seem convenient to speed up the process by wiping the skin or blowing air across it. However, these actions can interfere with the intended preparation process.

Wiping can remove antiseptic solution from the skin before the preparation is complete. Blowing directly onto the prepared area can also introduce unnecessary contamination.

The safer approach is simple: apply the product according to its validated instructions and allow it to dry naturally.

What About Procedures Near Sensitive Tissues?

Drying becomes particularly important when skin antisepsis is performed before procedures where residual antiseptic could potentially reach sensitive tissues.

Research involving CHG-alcohol preparations before neuraxial procedures has drawn attention to the importance of allowing the antiseptic to dry before needle insertion.

This does not mean that every CHG product has the same clinical restrictions. The formulation, concentration, application site, and intended use all matter.

For this reason, healthcare professionals should always follow the specific product labeling and applicable clinical protocols.

How Does the Applicator Design Affect Drying?

The applicator itself can influence how consistently the solution is distributed.

A well-designed CHG applicator should allow controlled delivery and help healthcare professionals achieve appropriate coverage without unnecessarily saturating the skin.

Using excessive solution does not automatically provide better antisepsis. It can instead increase the amount of liquid that must evaporate and may increase the possibility of pooling.

This is one reason that applicator volume and application technique should be matched to the intended preparation area.

As a medical-device manufacturer, Huachenyang (HCY) focuses on applicator design and manufacturing consistency to support practical clinical skin-preparation workflows.

A Practical Rule for CHG Skin Preparation

The key principle is straightforward:

Apply → Cover the required area → Allow to air dry → Proceed according to the clinical protocol.

Drying should not be treated as an insignificant waiting period. It is part of the skin-preparation process and, with alcohol-based CHG products, an important safety consideration.

For healthcare professionals using CHG applicators, following the product IFU, avoiding excessive solution, preventing pooling, and allowing adequate natural drying can help make skin antisepsis more consistent and safer in clinical practice.

This article is intended for general educational purposes. Always follow the specific product IFU, applicable regulations, and institutional clinical protocols.

In 2026, several key trends are shaping TOC sampling, including low-TOC background containers, improved sample integrity, certification, automation compatibility, and updated pharmaceutical water requirements.

1. Low-TOC Background Is Becoming More Important

TOC analysis measures very low levels of organic carbon, which means contamination from the sampling container itself can potentially affect results.

Possible sources include:

• Container materials and manufacturing residues
• Cleaning agents
• Caps and septa
• Improper handling
• Environmental contamination

For sensitive applications, laboratories increasingly choose low-TOC or TOC-certified containers. Some commercial products specify container backgrounds below 10 or 20 ppb TOC and provide certificates of analysis.

This highlights an important principle: reliable TOC testing starts with sample integrity, not only the analyzer.

2. TOC Certification and Traceability

Another important trend is greater emphasis on documented container quality.

For controlled laboratory and pharmaceutical applications, useful documentation may include:

• TOC background specifications
• Certificate of Analysis (COA)
• Batch or lot identification
• Cleaning information
• Manufacturing and packaging specifications

Such documentation helps laboratories improve consistency and traceability when establishing their sampling procedures.

3. The 2026 European Pharmacopoeia Update

A significant regulatory development in 2026 is the update to the European Pharmacopoeia requirements for pharmaceutical water.

The revised Chapter 2.2.44, “Total Organic Carbon in Water for Pharmaceutical Use,” became applicable on July 1, 2026. The revision includes changes to TOC testing and introduces Method B for sterilised water for injections (SWFI).

These changes make appropriate sampling procedures and container selection increasingly relevant for laboratories working with pharmaceutical water.

4. Compatibility With Automated TOC Analysis

Laboratory automation is also influencing TOC container design.

As autosamplers become more common, containers need to match the laboratory’s equipment and workflow. Important considerations include:

• Container dimensions
• Sample volume
• Closure design
• Autosampler compatibility
• Sample identification and handling

TOC-certified containers are already available in formats designed for automated sampling systems.

5. How to Choose a TOC Sample Bottle

When selecting a TOC sample bottle, laboratories should consider more than capacity.

Low TOC Background
The container should introduce minimal additional organic carbon.

Material Compatibility
The material should be appropriate for the sample and analytical procedure.

Reliable Closure
A secure closure helps protect samples from contamination during storage and transportation.

Cleaning and Certification
Pre-cleaned or certified containers can provide better control for sensitive applications.

Instrument Compatibility
For automated testing, the container should be compatible with the laboratory’s autosampler.

6. The Future of TOC Sampling

The overall trend is moving toward better control of the entire sampling workflow, rather than focusing only on the TOC analyzer.

Future developments are likely to continue around:

• Lower container background
• Improved cleaning processes
• Better certification and traceability
• Automation compatibility
• More standardized sampling procedures

For laboratories performing sensitive TOC analysis, the sample container should therefore be considered an integral part of the testing process.

Huachenyang TOC Sampling Solutions

Huachenyang develops and manufactures laboratory and medical sampling products for professional testing applications.

Our TOC sampling solutions focus on practical requirements such as consistent manufacturing quality, reliable sealing, appropriate container design, and controlled sample handling.

For laboratories, pharmaceutical manufacturers, distributors, and OEM/ODM customers, Huachenyang provides professional sampling solutions designed for different application requirements.

Key Factors of a Reliable Stool Collection Tube

1. Low-Temperature Resistant Material

Material selection is the foundation of low-temperature performance. Polypropylene (PP) is widely used for laboratory tubes because of its chemical resistance and suitability for low-temperature applications.

However, using PP alone does not guarantee performance at a specific temperature. Polymer grade, tube thickness, structure, and manufacturing quality can all affect resistance to cracking, deformation, and brittleness.

2. Structural Integrity

Freezing can change the mechanical behavior of plastic materials. A suitable stool collection tube should maintain its shape and physical integrity throughout the intended storage temperature range.

Important design factors include:

Resistance to cracking and deformation

Consistent tube wall thickness

Stable tube geometry

Durable bottom structure

Suitable cap and tube interface

3. Reliable Sealing and Leak Resistance

Low-temperature storage can place additional demands on the tube and closure system. A secure seal helps prevent leakage, contamination, and sample loss during freezing and transportation.

For this reason, the tube and cap should be evaluated as a complete system, rather than considering the tube material alone.

4. Freeze-Thaw Performance

Some laboratory workflows involve repeated freezing and thawing. Temperature cycling can place additional mechanical stress on both the tube and its closure.

Performance evaluation may include:

• Low-temperature exposure
• Freeze-thaw cycles
• Visual inspection
• Cap integrity
• Leakage testing
• Dimensional stability

The appropriate test conditions should be based on the intended application and validated product specifications.

5. Clearly Defined Temperature Performance

“Low-temperature resistant” should not be treated as a vague marketing claim. Buyers should look for a clearly defined and validated temperature range.

For example, commercial laboratory tubes may specify storage temperatures of -80°C or lower, depending on their material, design, and intended application. Some stool preservation products also identify freezer compatibility as a product feature.

The manufacturer’s specifications should distinguish between:

Storage temperature · Operating temperature · Freeze-thaw conditions · Cryogenic storage

Choosing a Low-Temperature Stool Collection Tube

When selecting a stool sample collection tube, laboratories and IVD buyers should consider:

Huachenyang Low-Temperature Resistant Stool Collection Tube

Huachenyang Low-Temperature Resistant Stool Collection Tube is designed for stool sample collection workflows where reliable handling under low-temperature conditions is required.

Its performance can be evaluated from several key aspects, including material selection, tube structure, sealing performance, low-temperature resistance, and sample containment.

For laboratories, diagnostic companies, IVD manufacturers, and distributors, selecting a properly validated stool collection tube can help support reliable sample collection, cold-chain transportation, and laboratory processing.

Conclusion

A reliable Low-Temperature Resistant Stool Collection Tube is more than a container that can withstand cold temperatures. Material properties, structural integrity, sealing performance, leakage resistance, and validated temperature performance all contribute to dependable sample handling.

For cold-storage and cold-chain workflows, these factors provide a practical basis for selecting the right stool collection tube for laboratory and diagnostic applications.

For more than a decade, Huachenyang (HCY) has developed and supplied viral transport media and specimen collection products for diagnostic and research applications. Today, Huachenyang’s iClean Viral Transport System (VTM-RT Kit)is listed with the U.S. FDA under 510(k) K212856, with the FDA identifying Huachenyang as the manufacturer of the non-propagating transport system.

VTM Used in Peer-Reviewed Infectious Disease Research

Huachenyang VTM and specimen collection products have appeared in published research involving SARS-CoV-2 testing and viral surveillance.

In a study conducted by researchers at the University of New South Wales (UNSW) Kirby Institute, the commercial HCY-CV19-UTM, Cat. No. CY-F003-40, was specifically evaluated as a viral transport medium in SARS-CoV-2 research.

Huachenyang collection products were also documented in Qatar’s large-scale SARS-CoV-2 testing system. Research published in Scientific Reports reported the use of Huachenyang swabs for nasopharyngeal and oropharyngeal specimen collection, with samples placed in Universal Transport Medium and subsequently processed using multiple molecular testing platforms.

Other peer-reviewed studies from Qatar similarly documented Huachenyang collection products in research involving COVID-19 epidemiology, reinfection, risk assessment, and variant surveillance.

These publications demonstrate the role of Huachenyang products in real-world specimen collection and infectious disease research—not simply in laboratory product testing.

FDA 510(k) VTM for Professional Diagnostic Applications

Huachenyang’s iClean Viral Transport System (VTM-RT Kit) received FDA 510(k) substantial equivalence determination under K212856. The FDA describes the device as a non-propagating transport system intended for the collection and transport of viral specimens for laboratory culture and downstream testing.

The FDA’s current device listing continues to identify Huachenyang as the manufacturer of the iClean Viral Transport System and related VTM/UTM products.

For international laboratories, diagnostic companies, distributors, and OEM buyers, this provides an important foundation when evaluating a VTM manufacturer or viral transport medium supplier.

Built for Long-Term VTM Supply

Huachenyang combines established VTM manufacturing experience with GMP production facilities, cleanroom capabilities, quality management systems, and international regulatory certifications. Its current product range includes multiple viral transport medium formats and volumes for different specimen collection workflows.

Whether the requirement is for routine molecular diagnostics, infectious disease surveillance, laboratory testing, or OEM supply, Huachenyang provides a mature VTM kit and viral specimen collection solution designed for consistent, scalable supply.

Looking for a reliable VTM manufacturer or FDA 510(k) VTM supplier? Contact Huachenyang to discuss your VTM, UTM, specimen collection, OEM, and bulk supply requirements.

From Liquid Saliva to Dried Samples

Traditional saliva collection relies on tubes that store samples in liquid form. While effective, liquid samples require suitable containers, packaging, storage, and transportation.

The development of dried biological sample technologies, particularly Dried Blood Spot (DBS) collection, demonstrated that biological materials could be collected onto an absorbent matrix, dried, and transported in a compact format.

This concept helped establish the foundation for card-based biological sample collection.

Why Saliva Became a DNA Sample

As PCR, genetic testing, and molecular research developed, saliva gained attention as a convenient and non-invasive source of human DNA.

Unlike blood collection, saliva collection generally does not require needles or venipuncture. This makes it useful for:

• Genetic testing
• DNA research
• Genotyping
• Population studies
• Pharmacogenomics
• Epidemiological research

The focus therefore shifted from simply collecting saliva to improving saliva DNA collection, preservation, and transportation.

The Development of Saliva Collection Cards

A Saliva Collection Card applies the dried-sample concept to saliva-based biological material.

A typical workflow is:

Saliva Collection → Sample Absorption → Drying → Storage/Transportation → DNA Extraction → Molecular Testing

Compared with conventional liquid saliva collection, a card format can provide a compact and convenient approach for certain decentralized and large-scale collection workflows.

The key value is not simply the card itself, but its role in the pre-analytical stage of DNA testing.

Saliva Collection Cards Today

Modern Saliva DNA Collection Cards can be designed with dedicated collection areas, sample identification, protective packaging, and compatibility with validated DNA extraction workflows.

Potential applications include:

• Genetic testing
• Molecular research
• Population studies
• Biobanking
• Clinical research
• Decentralized sample collection

For laboratories and genetic testing companies, the ideal solution connects:

Sample Collection → Preservation → Transportation → DNA Extraction → Molecular Analysis

Huachenyang Saliva Collection Solutions

Huachenyang develops biological sample collection and preservation products, including Saliva Collection Cards, DNA collection products, specimen collection swabs, and sample preservation solutions.

The development of saliva collection technology reflects a broader trend in molecular diagnostics: making biological sample collection simpler, more accessible, and easier to integrate with downstream laboratory testing.

For laboratories, diagnostic companies, research institutions, and distributors, a reliable Saliva Collection Card can provide a practical starting point for modern saliva DNA collection workflows.

FAQ

What is a Saliva Collection Card?
A Saliva Collection Card is a card-based device designed to collect saliva-derived biological material for subsequent laboratory analysis.

Can a Saliva Collection Card be used for DNA testing?
Yes. When properly designed and validated, it can be used as part of a saliva DNA collection and molecular testing workflow.

Why use a Saliva Collection Card?
It provides a compact, non-invasive sample collection format that can be suitable for certain research, genetic testing, and decentralized collection applications.